State of New Jersey Common Pension Fund D Acquires 16,591 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

State of New Jersey Common Pension Fund D increased its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 178.5% in the 3rd quarter, Holdings Channel reports. The fund owned 25,886 shares of the company’s stock after buying an additional 16,591 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Immunocore were worth $940,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. GAMMA Investing LLC increased its stake in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in Immunocore during the 2nd quarter valued at approximately $42,000. Osaic Holdings Inc. increased its position in Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after buying an additional 1,700 shares in the last quarter. State of Tennessee Department of Treasury purchased a new position in Immunocore during the second quarter valued at $132,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in Immunocore in the second quarter worth $248,000. Institutional investors own 84.50% of the company’s stock.

Analyst Ratings Changes

IMCR has been the subject of several recent analyst reports. Mizuho set a $38.00 price target on Immunocore in a research report on Thursday, February 19th. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. UBS Group set a $55.00 price objective on shares of Immunocore and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $61.30.

Immunocore Price Performance

Shares of IMCR opened at $32.04 on Friday. The firm has a fifty day simple moving average of $33.55 and a two-hundred day simple moving average of $34.32. The firm has a market cap of $1.62 billion, a PE ratio of -45.77 and a beta of 0.78. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $23.15 and a 1-year high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.32). Immunocore had a negative return on equity of 9.16% and a negative net margin of 8.88%.The firm had revenue of $104.48 million during the quarter, compared to the consensus estimate of $145.48 million. During the same period in the previous year, the firm earned ($0.47) EPS. The business’s revenue was up 24.3% on a year-over-year basis. On average, equities analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current year.

Key Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target from $71 to $75 and kept a Buy rating, implying substantial upside vs. the current share price. Benzinga
• Positive Sentiment: Strong product sales and cash runway — KIMMTRAK net sales were $104.5M in Q4 and $400M for FY2025; company ended the year with ~$864.2M in cash, cash equivalents and marketable securities, supporting R&D and runway. Press Release
• Positive Sentiment: Near-term clinical catalysts — Management expects TEBE‑AM enrollment completion 1H2026 with topline as early as 2H2026; multiple PRAME franchise and HIV Phase 1/2 readouts also slated in 2H2026 — potential value-inflecting events. Pipeline Update
• Neutral Sentiment: Full earnings materials available — Management hosted a conference call and released slide deck and transcripts; these provide color on commercialization, trial timelines and cost structure. Earnings Transcript
• Negative Sentiment: Quarterly misses and guidance tone — Q4 EPS of ($0.60) missed consensus (~($0.28)) and revenue of $104.48M materially missed the ~$145M estimate; company cautioned that revenue growth will moderate in 2026, which reduces near-term upside. Earnings Release / Slide Deck

Insider Activity

In related news, insider Leger Tina Amber St sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider directly owned 1,119 shares in the company, valued at approximately $36,199.65. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David M. Berman sold 5,965 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the transaction, the insider owned 5,859 shares in the company, valued at $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 19,137 shares of company stock valued at $619,082 in the last quarter. 10.40% of the stock is currently owned by insiders.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.